Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vi

Broker, Joachim; Waterson, Alex G.; Smethurst, Chris; Kessler, Dirk; Bottcher, Jark; Mayer, Moriz; Gmaschitz, Gerhard; Phan, Jason; Little, Andrew; Abbott, Jason R.; Sun, Qi; Gmachl, Michael; Rudolph, Dorothea; Arnhof, Heribert; Rumpel, Klaus; Savarese, Fabio; Gerstberger, Thomas; Mischerikow, Nikolai; Treu, Matthias; Herdeis, Lorenz; Wunberg, Tobias; Gollner, Andreas; Weinstabl, Harald; Mantoulidis, Andreas; Kramer, Oliver; McConnell, Darryl B.; Fesik, Stephen W.

doi:10.1021/acs.jmedchem.2c01120

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vi

Journal Article · 01 October 2022 · J. Med. Chem.

DOI:https://doi.org/10.1021/acs.jmedchem.2c01120· OSTI ID:1902372

Broker, Joachim; Waterson, Alex G.; Smethurst, Chris; Kessler, Dirk; Bottcher, Jark; Mayer, Moriz; Gmaschitz, Gerhard; Phan, Jason; Little, Andrew; Abbott, Jason R.; Sun, Qi; Gmachl, Michael; Rudolph, Dorothea; Arnhof, Heribert; Rumpel, Klaus; Savarese, Fabio; Gerstberger, Thomas; Mischerikow, Nikolai; Treu, Matthias; Herdeis, Lorenz more »

Research Organization:: Advanced Photon Source (APS), Argonne National Laboratory (ANL), Argonne, IL (US)

Sponsoring Organization:: DOE - Office Of Science; NIH

OSTI ID:: 1902372

Journal Information:: J. Med. Chem., Journal Name: J. Med. Chem. Journal Issue: (21) Vol. 65

Country of Publication:: United States

Language:: ENGLISH

References (30)

The Frequency of Ras Mutations in Cancer Prior, Ian A.; Hood, Fiona E.; Hartley, James L. Cancer Research, Vol. 80, Issue 14 https://doi.org/10.1158/0008-5472.can-19-3682	journal	March 2020
Discovery of a Covalent Inhibitor of KRAS ^G12C (AMG 510) for the Treatment of Solid Tumors Lanman, Brian A.; Allen, Jennifer R.; Allen, John G. Journal of Medicinal Chemistry, Vol. 63, Issue 1 https://doi.org/10.1021/acs.jmedchem.9b01180	journal	December 2019
RAS-targeted therapies: is the undruggable drugged? Moore, Amanda R.; Rosenberg, Scott C.; McCormick, Frank Nature Reviews Drug Discovery, Vol. 19, Issue 8 https://doi.org/10.1038/s41573-020-0068-6	journal	June 2020
Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation Sun, Qi; Burke, Jason P.; Phan, Jason Angewandte Chemie International Edition, Vol. 51, Issue 25 https://doi.org/10.1002/anie.201201358	journal	May 2012
High-Throughput Kinetic Characterization of Irreversible Covalent Inhibitors of KRAS^G12C by Intact Protein MS and Targeted MRM Li, Ke Sherry; Quinn, John G.; Saabye, Matthew J. Analytical Chemistry, Vol. 94, Issue 2 https://doi.org/10.1021/acs.analchem.1c04463	journal	January 2022
Drugging all RAS isoforms with one pocket Kessler, Dirk; Bergner, Andreas; Böttcher, Jark Future Medicinal Chemistry, Vol. 12, Issue 21 https://doi.org/10.4155/fmc-2020-0221	journal	November 2020
The KRAS ^G12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients Hallin, Jill; Engstrom, Lars D.; Hargis, Lauren Cancer Discovery, Vol. 10, Issue 1 https://doi.org/10.1158/2159-8290.cd-19-1167	journal	October 2019
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors Davies, Christopher W.; Oh, Angela J.; Mroue, Rana Nature Biotechnology, Vol. 40, Issue 5 https://doi.org/10.1038/s41587-021-01126-9	journal	January 2022
Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity Lonsdale, Richard; Burgess, Jonathan; Colclough, Nicola Journal of Chemical Information and Modeling, Vol. 57, Issue 12 https://doi.org/10.1021/acs.jcim.7b00553	journal	November 2017
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism Lito, P.; Solomon, M.; Li, L. -S. Science, Vol. 351, Issue 6273 https://doi.org/10.1126/science.aad6204	journal	January 2016
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Vigil, Dominico; Cherfils, Jacqueline; Rossman, Kent L. Nature Reviews Cancer, Vol. 10, Issue 12 https://doi.org/10.1038/nrc2960	journal	November 2010
Drugging an undruggable pocket on KRAS Kessler, Dirk; Gmachl, Michael; Mantoulidis, Andreas Proceedings of the National Academy of Sciences, Vol. 116, Issue 32 https://doi.org/10.1073/pnas.1904529116	journal	July 2019
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity Maurer, T.; Garrenton, L. S.; Oh, A. Proceedings of the National Academy of Sciences, Vol. 109, Issue 14 https://doi.org/10.1073/pnas.1116510109	journal	March 2012
A Ras-induced conformational switch in the Ras activator Son of sevenless Freedman, T. S.; Sondermann, H.; Friedland, G. D. Proceedings of the National Academy of Sciences, Vol. 103, Issue 45 https://doi.org/10.1073/pnas.0608127103	journal	October 2006
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity Canon, Jude; Rex, Karen; Saiki, Anne Y. Nature, Vol. 575, Issue 7781 https://doi.org/10.1038/s41586-019-1694-1	journal	October 2019
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants Hofmann, Marco H.; Gerlach, Daniel; Misale, Sandra Cancer Discovery, Vol. 12, Issue 4 https://doi.org/10.1158/2159-8290.cd-21-1331	journal	January 2022
BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition Hofmann, Marco H.; Gmachl, Michael; Ramharter, Juergen Cancer Discovery, Vol. 11, Issue 1 https://doi.org/10.1158/2159-8290.cd-20-0142	journal	January 2021
Human RAS Superfamily Proteins and Related GTPases Colicelli, J. Science Signaling, Vol. 2004, Issue 250 https://doi.org/10.1126/stke.2502004re13	journal	September 2004
Using chemical shift perturbation to characterise ligand binding Williamson, Mike P. Progress in Nuclear Magnetic Resonance Spectroscopy, Vol. 73 https://doi.org/10.1016/j.pnmrs.2013.02.001	journal	August 2013
Identification of the Clinical Development Candidate MRTX849 , a Covalent KRAS ^G12C Inhibitor for the Treatment of Cancer Fell, Jay B.; Fischer, John P.; Baer, Brian R. Journal of Medicinal Chemistry, Vol. 63, Issue 13 https://doi.org/10.1021/acs.jmedchem.9b02052	journal	April 2020
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors Kwan, Albert K.; Piazza, Gary A.; Keeton, Adam B. Journal of Experimental & Clinical Cancer Research, Vol. 41, Issue 1 https://doi.org/10.1186/s13046-021-02225-w	journal	January 2022
RAS Proteins and Their Regulators in Human Disease Simanshu, Dhirendra K.; Nissley, Dwight V.; McCormick, Frank Cell, Vol. 170, Issue 1 https://doi.org/10.1016/j.cell.2017.06.009	journal	June 2017
Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity Reßing, Nina; Marquardt, Viktoria; Gertzen, Christoph G. W. MedChemComm, Vol. 10, Issue 7 https://doi.org/10.1039/c8md00454d	journal	January 2019
Abstract 1271: In vitro and in vivo characterization of BI 1823911 - a novel KRASG12C selective small molecule inhibitor Savarese, Fabio; Gollner, Andreas; Rudolph, Dorothea Cancer Research, Vol. 81, Issue 13_Supplement https://doi.org/10.1158/1538-7445.am2021-1271	journal	July 2021
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions Ostrem, Jonathan M.; Peters, Ulf; Sos, Martin L. Nature, Vol. 503, Issue 7477 https://doi.org/10.1038/nature12796	journal	November 2013
A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand Sun, Qi; Phan, Jason; Friberg, Anders R. Journal of Biomolecular NMR, Vol. 60, Issue 1 https://doi.org/10.1007/s10858-014-9849-8	journal	August 2014
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State Patricelli, M. P.; Janes, M. R.; Li, L. -S. Cancer Discovery, Vol. 6, Issue 3 https://doi.org/10.1158/2159-8290.cd-15-1105	journal	January 2016
The structural basis of the activation of Ras by Sos Boriack-Sjodin, P. Ann; Margarit, S. Mariana; Bar-Sagi, Dafna Nature, Vol. 394, Issue 6691 https://doi.org/10.1038/28548	journal	July 1998
Intrinsic reactivity profile of electrophilic moieties to guide covalent drug design: N-α-acetyl-l-lysine as an amine nucleophile Dahal, Upendra P.; Gilbert, Adam M.; Obach, R. Scott MedChemComm, Vol. 7, Issue 5 https://doi.org/10.1039/c6md00017g	journal	January 2016
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS^G12D Inhibitor Wang, Xiaolun; Allen, Shelley; Blake, James F. Journal of Medicinal Chemistry, Vol. 65, Issue 4 https://doi.org/10.1021/acs.jmedchem.1c01688	journal	December 2021

Similar Records

Optimization of a binding fragment targeting the “enlarged methionine pocket” leads to potent Trypanosoma brucei methionyl-tRNA synthetase inhibitors

Journal Article · 2017 · Bioorganic and Medicinal Chemistry Letters · OSTI ID:1416585

Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors

Journal Article · 2023 · Proceedings of the National Academy of Sciences of the United States of America · OSTI ID:2423430

Drugging an undruggable pocket on KRAS

Journal Article · 2019 · Proceedings of the National Academy of Sciences of the United States of America · OSTI ID:1593440

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vi

Citation Formats

References (30)

Similar Records

Related Subjects